Through innovative studies of the treatment of HIV-1 infection and its complications, ACTG research focuses on:
New therapies based on knowledge of the cellular events and reactions in the development of disease (pathogenesis)
Treatment strategies to limit replication of HIV-1 and improve disease-free survival among infected individuals
Rapid development of agents (drugs or treatment strategies) that prevent or delay the complications of HIV-related disorders
HIV-1 pathogenesis through advanced laboratory investigation
Recruitment and retention of clinical trial participants who reflect the changing demographics of the AIDS epidemic
Therapeutic approaches that improve quality of life for persons with HIV-1 infection
History
The ACTG has been pivotal[citation needed] in providing the data necessary for the approval of therapeutic agents, as well as treatment and prevention strategies, for many opportunistic infections and malignancies.
In 1986, the original AIDS Treatment and Evaluation Units were established by the National Institutes of Health.
In 1987, the AIDS Clinical Trials Group (ACTG) was established by the National Institute of Allergy and Infectious Diseases.
In 1991, the ACTG divided its focus into two groups and created the Adult ACTG (AACTG) and the Pediatric ACTG (PACTG).
In 1995 the AACTG restructured and created a true self-governing structure, with self-evaluation of sites, priority setting of scientific research, discretionary spending. The PACTG became its own group and an AIDS Malignancy Consortium was established under the National Cancer Institute.
In 1999 the AACTG applied for continued funding as an investigator led and run group
In 2000, the AACTG began the planning and development of international research initiatives in the developing world.
In 2005, the ACTG opened its first multinational AIDS clinical trial in 16 sites around the globe “A Phase IV, Prospective, Randomized, Open-Label Evaluation of the Efficacy of Once-Daily PI & Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor - Containing Therapy Combinations for Initial Treatment of HIV-1 Infected individuals from Resource - Limited Settings (PEARLS) Trial”, the results of which suggested men and women respond to antiretroviral drugs differently.[1]
In 2006, the network was funded as one of the six NIAID-funded HIV/AIDS Clinical Trials Networks.[2]
